ASCLETIS-B

1672
4.2758.95% ( -0.420 )
Delay Closed: Nov 16, 16:08:11

Overview

ASCLETIS-B (1672)

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland...

Open
4.500
High
4.630
Low
4.215
Prev. Close
4.695
Volume
1.55M
Turnover
6.71M
Avg Price
4.338
Bid/Ask Ratio
45.45%
Amplitude
8.84%
52wk High
19.860
Volume Ratio
0.43
Turnover Ratio
0.15%
52wk Low
4.115
HK Mkt Cap
4.50B
Market CapHKD
4.50B
P/ETTM
Loss
P/EDynamic
Loss
P/EStatic
--
EPSTTM
-0.647
EPSDynamic
-0.700
EPSStatic
--
BVPS
2.48
P/B
1.72
HK Shares
1.05B
Dividend YieldTTM
--
DividendTTM
--
Shares
1.05B
Min lot size
1,000
Currency
HKD

ASCLETIS-B Analyst Rating

View more

Forecast & Rating

Sep 2, 2026
Price forecast
HK$22.43424.66%
Forecast & RatingBuy
3analysts
  • Strong buy33.33%
  • Buy33.33%
  • Hold33.33%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 16

    Ascletis Pharma fell 9.1% to HK$4.270 on 16 November from the prior close of HK$4.695 on HK$6.54 million turnover, tracing a one-way decline: it opened at HK$4.695 in the morning session, slid to HK$4.410 by the 11:59 break and touched an intraday low of HK$4.220 at 13:59 before a small close-of-day recovery. News flow centred on an FDA IND filing for ASC30_39 in obesity, several buyback-for-cancellation filings and a grant of 1.8 million employee options, while early readouts — ASC37's half-life six times longer than retatrutide and a 1.7% HbA1c cut at 12 weeks for the oral GLP-1 — have yet to generate revenue; Q2 2026 EPS was -HK$0.1776 and the net loss of HK$184.6 million widened 283% year on year. The price sits just 3.8% above its 52-week low of HK$4.115, is down 62.9% year to date, 78.5% below the April 19 high of HK$19.86, and under the MA20 of HK$5.023 and MA60 of HK$7.553, though repeated buybacks and a 1.72x PB against a negative PE indicate pricing still tracks pipeline expectations rather than current earnings.

  2. Nov, 13

    Ascletis Pharma reversed an early slide to close at HK$4.85, up 0.21% from HK$4.84, after touching 4.64 at 09:31 BJ and 4.58 at 14:50 BJ before recovering to 4.85 near the 4.86 intraday high; volume of 2.331 million shares (HK$10.96 million) and a thin 0.22% turnover rate point to sentiment repair rather than fresh capital. Pipeline headlines clustered: an FDA IND filing for ASC30_39 in obesity, ASC37's half-life reported six-fold longer than retatrutide, and oral GLP-1 cutting HbA1c 1.7 percentage points versus placebo at 12 weeks, alongside repeated buyback-for-cancellation disclosures. Fundamentals still lag, with Q2 EPS of -HK$0.1776 and a net loss of HK$184.6 million that widened 283% year on year, ROE at -28.15%, while the price sits below MA20 of 5.11 and MA60 of 7.65, down 57.9% year to date, 75.6% under the 52-week high of 19.86 and just 17.9% above the November 3 low of 4.115, though a PE of -7.49 shows earnings support is still absent.

  3. Nov, 12

    Ascletis opened at 4.775, dipped to 4.675 at 09:43 BJ, then reversed higher after the company filed an FDA IND application for its ASC30/ASC39 obesity programme, peaking at 5.060 at 13:15 BJ before paring gains to close at 4.950 HKD, up 3.66% on 2.8 million shares worth 13.72 million HKD; repeated buybacks for cancellation also eased selling pressure after the stock touched a 52-week low of 4.115 on 3 November. Pipeline disclosures added support: ASC37 showed a half-life six times longer than retatrutide, and the oral GLP-1 cut HbA1c by 1.7% versus placebo at 12 weeks. Fundamentals remain weak, with a Q2 2026 net loss of 184.6 million HKD widening 283% year on year, EPS of -0.1776 HKD, ROE of -28.15% and no reported revenue, leaving PE negative and PB at 1.99. At 4.950 the stock sits below MA20 of 5.159 and MA60 of 7.739, down 57.03% year to date, 75.08% below its 52-week high of 19.86 and only 20.29% above the low. Though the buyback and IND filing still await clinical validation.

  4. Nov, 9

    Ascletis-B rose 7.3% to HK$4.88, extending a rebound from the 52-week low of HK$4.115 set on 3 November, as buybacks and ObesityWeek 2026 disclosures reinforced each other: the company repurchased 200,000 shares for HK$960,600 on 5 November and 100,000 shares for HK$459,700 on 6 November, while data showed ASC37's half-life roughly six times longer than retatrutide and the oral GIPR agonist ASC48 was presented at the same conference. Intraday the stock spiked to HK$5.045 at 09:32 in the morning session, sank to HK$4.655 at 15:46 in the afternoon and closed at HK$4.88 on 2.135 million shares worth HK$10.28 million, a thin 0.20% turnover rate. Fundamentals remain weak: the Q2 2026 net loss was HK$184.6 million, 283% wider year on year, with EPS of -HK$0.1776; the shares sit below the MA20 of HK$5.407 and MA60 of HK$8.014, down 57.64% year to date and 75.43% below the 19 April peak of HK$19.86. Whether the buyback pace near the 52-week low persists is still to be seen.

  5. Nov, 6

    Ascletis fell 7.8% to HK$4.515 after opening at HK$4.710, briefly rising to HK$4.735 and later sliding to HK$4.505, as the Hong Kong innovative-drug complex weakened again; GENSCRIPT BIO dropped over 15%, KEYMED BIO-B nearly 5%, and the Life Sciences Index fell for a fourth session. The company bought back 200,000 shares for HK$960,600 on November 5, which did not arrest the decline. Q2 2026 net loss was HK$184.6 million, 283% wider year on year, with EPS at -HK$0.1776. The stock sits 77.3% below its 52-week high of HK$19.86, down 60.8% YTD, and below MA20 of HK$5.52 and MA60 of HK$8.115. Still, ASC30 oral GLP-1 achieved a 1.7% placebo-adjusted HbA1c reduction at week 12 in a Phase II diabetes trial, while ASC37's half-life is six-fold longer than retatrutide, offering a counterpoint.

News